Background: Different treatments have been developed and used to control symptoms and improve quality of life in patients with digestive diseases and disorders. Although the use of drugs or alternative approaches has ...Background: Different treatments have been developed and used to control symptoms and improve quality of life in patients with digestive diseases and disorders. Although the use of drugs or alternative approaches has improved symptom severity in some but not all patients, often these improvements were not sustainable. Objectives: An open label clinical study was initiated to determine if oral capsules containing a dietary supplement of herbs and oils (GI RegenerateTM) could reduce self-reported gastrointestinal symptoms and improve quality of life (QOL) indicators in patients with gastrointestinal conditions. Methods: Participants included 50 patients (40 females and 10 males) of mean age of 51.1 ± 12.7 years (range, 24 - 77 years) with a diagnosis of a gastrointestinal disorder or gastrointestinal symptoms. These patients consumed five soft-gels containing the test supplement 30 minutes before each meal for 90 days. Symptoms were evaluated by medical staff, and patient health status was self-reported using a validated quality of life questionnaire (Quality of Life Digestive Survey) designed for functional digestive disorders. Exit interviews (Patient Global Impression of Change, PGIC) were conducted by the medical staff. Results: Participants in the study responded with improved symptom severities and QOL scores to the test dietary supplement within the 90 day period;most improvements occurred within 20 days on the test dietary supplement. By the end of the study there were significant overall global improvements in the symptoms and QOL health surveys (p = 0.0183), with significant improvements in symptom discomfort (p = 0.0004), daily activities (p = 0.029) and anxiety (p = 0.018). In contrast, there were insignificant improvements in diet (p = 0.398), sleep (p = 0.136), health perception (p = 0.686), coping with the disease (p = 0.309) and impact of stress (p = 0.785). Using the PGIC exit interview that measured each patient’s impression of overall global change in symptoms and QOL these data also indicated overall significant improvements in symptoms and in satisfaction with the test supplement (moderately better improvements in symptoms and QOL or score of 4.8 ± 0.169, p 50 years) versus younger (Conclusions: The GI RegenerateTM natural dietary supplement safely and significantly reduced gastrointestinal symptoms and improved quality of life in subjects with a broad spectrum of gastrointestinal disorders and symptoms.展开更多
AIM To find the association between asthma and different types of functional abdominal pain disorders(FAPDs) among teenagers. METHOD A cross-sectional study was conducted among 13 to 15-year-old children from six rand...AIM To find the association between asthma and different types of functional abdominal pain disorders(FAPDs) among teenagers. METHOD A cross-sectional study was conducted among 13 to 15-year-old children from six randomly selected schools in Anuradhapura district of Sri Lanka. Data were collected using translated and validated selfadministered questionnaires(Rome Ⅲ questionnaire, International Study on Asthma and Allergies in Childhood questionnaire, and Pediatric Quality of Life Inventory 4.0) and administered under an examination setting after obtaining parental consent and assent.RESULTS Of the 1101 children included in the analysis, 157(14.3%) had asthma and 101(9.2%) had at least one FAPDs. Of children with asthma, 19.1% had at least one type of FAPDs. Prevalence rates of functional abdominal pain(FAP)(8.9% vs 3.3% in nonasthmatics), functional dyspepsia(FD)(2.5% vs 0.7%), and abdominal migraine(AM)(3.2% vs 0.4%) were higher in those with asthma(P < 0.05, multiple logistic regression analysis), but not in those with irritable bowel syndrome(4.5% vs 3.1%, P = 0.2). Severe abdominal pain(10.8% vs 4.6%), bloating(16.6% vs 9.6%), nausea(6.4% vs 2.9%), and anorexia(24.2% vs 16.2%) were more prevalent among asthmatics(P < 0.05). Lower gastrointestinal symptoms did not show a significant difference. Scores obtained for health related quality of life(HRQoL) were lower in those with asthma and FAPDs(P < 0.05, unpaired t-test).CONCLUSION Asthma is associated with three different types of FAPDs, namely, FD, AM, and FAP. HRQoL is significantly impaired in teenagers with asthma and FAPDs.展开更多
目的探讨头针联合吞咽功能康复训练治疗中风后假性球麻痹吞咽障碍患者的临床疗效。方法选取2023年1月—2023年12月期间保定市第一中心医院收治的中风后假性球麻痹吞咽障碍患者80例,按照随机对照试验设计方法分为对照组和观察组,每组各4...目的探讨头针联合吞咽功能康复训练治疗中风后假性球麻痹吞咽障碍患者的临床疗效。方法选取2023年1月—2023年12月期间保定市第一中心医院收治的中风后假性球麻痹吞咽障碍患者80例,按照随机对照试验设计方法分为对照组和观察组,每组各40例。对照组接受康复训练等常规西医治疗,观察组在对照组基础上联合头针治疗。治疗4周后,观察比较两组患者治疗前后中医证候积分、洼田氏饮水试验评分、Barthel指数评分、美国国立卫生研究院卒中量表(National institute of health stroke scale,NIHSS)评分、吞咽功能评估表(Standardized swallowing assessment,SSA)评分、吞咽障碍特异性生活质量量表(Swallowing quality of life,SWAL-QOL)评分改善状况,并比较两组患者临床总有效率和不良反应发生率。结果治疗后两组患者中医证候积分和洼田氏饮水试验评分均较治疗前降低,差异有统计学意义(P<0.05);且观察组中医证候积分和洼田氏饮水试验评分均低于对照组,差异有统计学意义(P<0.05)。治疗后两组患者Barthel指数评分较治疗前升高,NIHSS评分较治疗前降低,差异有统计学意义(P<0.05);且观察组Barthel指数评分高于对照组,NIHSS评分低于对照组,差异有统计学意义(P<0.05)。治疗后两组患者SSA评分较治疗前降低,SWAL-QOL评分较治疗前升高,差异有统计学意义(P<0.05);且观察组SSA评分低于对照组,SWAL-QOL评分高于对照组,差异有统计学意义(P<0.05)。治疗后观察组临床总有效率92.50%(37/40)高于对照组75.00%(30/40),差异有统计学意义(P<0.05)。治疗期间,两组患者均未出现晕针、血肿等不良反应发生情况。结论头针联合吞咽功能康复训练能改善中风后假性球麻痹吞咽障碍患者的神经损伤程度和吞咽功能,缓解患者临床症状表现,提高吞咽障碍患者生活质量,具有显著的临床疗效。展开更多
AIM: To study the efficacy of low-dose imipramine in relieving symptoms associated with the irritable bowel syndrome (IBS). METHODS: A randomized, double-blind trial of 25 mg imipramine vs matched placebo for 12 wk wa...AIM: To study the efficacy of low-dose imipramine in relieving symptoms associated with the irritable bowel syndrome (IBS). METHODS: A randomized, double-blind trial of 25 mg imipramine vs matched placebo for 12 wk was performed. Doubling the dose was allowed once at week 2 in case of an unsatisfactory early response. Primary efficacy variables were subjective global symptom relief and quality of life (QoL) using SF-36 at week 12. RESULTS: One hundred and seven patients were enrolled by advertisement or referral by general practitioners and 56 (31 imipramine: 25 placebo) completed the 16-wk study. Baseline characteristics were comparable. A high overall dropout rate was noted in the imipramine and placebo arms (47.5% vs 47.9%, P > 0.05), a mean of 25.0 and 37.4 d from enrollment, respectively (P < 0.05). At the end of 12 wk, there was a significant difference in global symptom relief with imipramine over placebo (per-protocol: 80.6% vs48.0%, P = 0.01) and a trend on intent-to-treat (ITT) analysis (42.4% vs 25.0%, P = 0.06). This improvement was evident early and persisted to week 16 (P = 0.024 and 0.053 by per-protocol and ITT analyses, respectively). Mean cumulative and componentspecific SF-36 scores improved in the imipramine group only (per-protocol, P < 0.01). Drug-related adverse events leading to patient dropout were more common in the imipramine group (25.4% vs 12.5%, P > 0.05). CONCLUSION: Imipramine may be effective in the treatment of IBS patients and is associated with improved QoL. Careful patient selection, initiation of a low dose with gradual escalation and monitoring for side effects may result in an improved therapeutic response.展开更多
目的系统评价家庭步行锻炼(HB-WE)对下肢动脉硬化闭塞症(ASO)患者步行能力和生活质量的影响。方法在中国知网、万方、维普、CBM、PubMed、Embase、Web of Science、the Cochrane Library数据库中检索、筛选自建库至2023年1月31日为止的H...目的系统评价家庭步行锻炼(HB-WE)对下肢动脉硬化闭塞症(ASO)患者步行能力和生活质量的影响。方法在中国知网、万方、维普、CBM、PubMed、Embase、Web of Science、the Cochrane Library数据库中检索、筛选自建库至2023年1月31日为止的HB-WE对ASO患者影响的随机对照试验文献,并提取所需数据。用Cochrane协作网风险偏倚评价工具进行质量评价、RevMan5.4软件进行Meta分析。结果在475篇文献中,最终纳入11项研究。Meta分析结果显示,与常规护理相比,HB-WE可提高ASO患者的步行能力[6 min步行距离(MD=22.03,95%CI:3.56~40.49,P=0.02),步行障碍问卷—距离(MD=9.49,95%CI:2.89~16.08,P=0.005),步行障碍问卷—速度(MD=6.63,95%CI:0.65~12.60,P=0.03),步行障碍问卷—爬楼梯(MD=7.72,95%CI:0.65~14.79,P=0.03)],但两者生活质量量表身体功能评分差异无统计学意义(MD=1.26,95%CI:-4.33~6.84,P=0.66)。结论HB-WE可提高ASO患者步行能力,但在提高生活质量方面尚无明显优势,还需更多的研究来论证。展开更多
文摘Background: Different treatments have been developed and used to control symptoms and improve quality of life in patients with digestive diseases and disorders. Although the use of drugs or alternative approaches has improved symptom severity in some but not all patients, often these improvements were not sustainable. Objectives: An open label clinical study was initiated to determine if oral capsules containing a dietary supplement of herbs and oils (GI RegenerateTM) could reduce self-reported gastrointestinal symptoms and improve quality of life (QOL) indicators in patients with gastrointestinal conditions. Methods: Participants included 50 patients (40 females and 10 males) of mean age of 51.1 ± 12.7 years (range, 24 - 77 years) with a diagnosis of a gastrointestinal disorder or gastrointestinal symptoms. These patients consumed five soft-gels containing the test supplement 30 minutes before each meal for 90 days. Symptoms were evaluated by medical staff, and patient health status was self-reported using a validated quality of life questionnaire (Quality of Life Digestive Survey) designed for functional digestive disorders. Exit interviews (Patient Global Impression of Change, PGIC) were conducted by the medical staff. Results: Participants in the study responded with improved symptom severities and QOL scores to the test dietary supplement within the 90 day period;most improvements occurred within 20 days on the test dietary supplement. By the end of the study there were significant overall global improvements in the symptoms and QOL health surveys (p = 0.0183), with significant improvements in symptom discomfort (p = 0.0004), daily activities (p = 0.029) and anxiety (p = 0.018). In contrast, there were insignificant improvements in diet (p = 0.398), sleep (p = 0.136), health perception (p = 0.686), coping with the disease (p = 0.309) and impact of stress (p = 0.785). Using the PGIC exit interview that measured each patient’s impression of overall global change in symptoms and QOL these data also indicated overall significant improvements in symptoms and in satisfaction with the test supplement (moderately better improvements in symptoms and QOL or score of 4.8 ± 0.169, p 50 years) versus younger (Conclusions: The GI RegenerateTM natural dietary supplement safely and significantly reduced gastrointestinal symptoms and improved quality of life in subjects with a broad spectrum of gastrointestinal disorders and symptoms.
文摘AIM To find the association between asthma and different types of functional abdominal pain disorders(FAPDs) among teenagers. METHOD A cross-sectional study was conducted among 13 to 15-year-old children from six randomly selected schools in Anuradhapura district of Sri Lanka. Data were collected using translated and validated selfadministered questionnaires(Rome Ⅲ questionnaire, International Study on Asthma and Allergies in Childhood questionnaire, and Pediatric Quality of Life Inventory 4.0) and administered under an examination setting after obtaining parental consent and assent.RESULTS Of the 1101 children included in the analysis, 157(14.3%) had asthma and 101(9.2%) had at least one FAPDs. Of children with asthma, 19.1% had at least one type of FAPDs. Prevalence rates of functional abdominal pain(FAP)(8.9% vs 3.3% in nonasthmatics), functional dyspepsia(FD)(2.5% vs 0.7%), and abdominal migraine(AM)(3.2% vs 0.4%) were higher in those with asthma(P < 0.05, multiple logistic regression analysis), but not in those with irritable bowel syndrome(4.5% vs 3.1%, P = 0.2). Severe abdominal pain(10.8% vs 4.6%), bloating(16.6% vs 9.6%), nausea(6.4% vs 2.9%), and anorexia(24.2% vs 16.2%) were more prevalent among asthmatics(P < 0.05). Lower gastrointestinal symptoms did not show a significant difference. Scores obtained for health related quality of life(HRQoL) were lower in those with asthma and FAPDs(P < 0.05, unpaired t-test).CONCLUSION Asthma is associated with three different types of FAPDs, namely, FD, AM, and FAP. HRQoL is significantly impaired in teenagers with asthma and FAPDs.
文摘目的探讨头针联合吞咽功能康复训练治疗中风后假性球麻痹吞咽障碍患者的临床疗效。方法选取2023年1月—2023年12月期间保定市第一中心医院收治的中风后假性球麻痹吞咽障碍患者80例,按照随机对照试验设计方法分为对照组和观察组,每组各40例。对照组接受康复训练等常规西医治疗,观察组在对照组基础上联合头针治疗。治疗4周后,观察比较两组患者治疗前后中医证候积分、洼田氏饮水试验评分、Barthel指数评分、美国国立卫生研究院卒中量表(National institute of health stroke scale,NIHSS)评分、吞咽功能评估表(Standardized swallowing assessment,SSA)评分、吞咽障碍特异性生活质量量表(Swallowing quality of life,SWAL-QOL)评分改善状况,并比较两组患者临床总有效率和不良反应发生率。结果治疗后两组患者中医证候积分和洼田氏饮水试验评分均较治疗前降低,差异有统计学意义(P<0.05);且观察组中医证候积分和洼田氏饮水试验评分均低于对照组,差异有统计学意义(P<0.05)。治疗后两组患者Barthel指数评分较治疗前升高,NIHSS评分较治疗前降低,差异有统计学意义(P<0.05);且观察组Barthel指数评分高于对照组,NIHSS评分低于对照组,差异有统计学意义(P<0.05)。治疗后两组患者SSA评分较治疗前降低,SWAL-QOL评分较治疗前升高,差异有统计学意义(P<0.05);且观察组SSA评分低于对照组,SWAL-QOL评分高于对照组,差异有统计学意义(P<0.05)。治疗后观察组临床总有效率92.50%(37/40)高于对照组75.00%(30/40),差异有统计学意义(P<0.05)。治疗期间,两组患者均未出现晕针、血肿等不良反应发生情况。结论头针联合吞咽功能康复训练能改善中风后假性球麻痹吞咽障碍患者的神经损伤程度和吞咽功能,缓解患者临床症状表现,提高吞咽障碍患者生活质量,具有显著的临床疗效。
基金Supported by A Private Research Fund From the Division of Gastroenterology at the American University of Beirut Medical Center, Beirut, Lebanon
文摘AIM: To study the efficacy of low-dose imipramine in relieving symptoms associated with the irritable bowel syndrome (IBS). METHODS: A randomized, double-blind trial of 25 mg imipramine vs matched placebo for 12 wk was performed. Doubling the dose was allowed once at week 2 in case of an unsatisfactory early response. Primary efficacy variables were subjective global symptom relief and quality of life (QoL) using SF-36 at week 12. RESULTS: One hundred and seven patients were enrolled by advertisement or referral by general practitioners and 56 (31 imipramine: 25 placebo) completed the 16-wk study. Baseline characteristics were comparable. A high overall dropout rate was noted in the imipramine and placebo arms (47.5% vs 47.9%, P > 0.05), a mean of 25.0 and 37.4 d from enrollment, respectively (P < 0.05). At the end of 12 wk, there was a significant difference in global symptom relief with imipramine over placebo (per-protocol: 80.6% vs48.0%, P = 0.01) and a trend on intent-to-treat (ITT) analysis (42.4% vs 25.0%, P = 0.06). This improvement was evident early and persisted to week 16 (P = 0.024 and 0.053 by per-protocol and ITT analyses, respectively). Mean cumulative and componentspecific SF-36 scores improved in the imipramine group only (per-protocol, P < 0.01). Drug-related adverse events leading to patient dropout were more common in the imipramine group (25.4% vs 12.5%, P > 0.05). CONCLUSION: Imipramine may be effective in the treatment of IBS patients and is associated with improved QoL. Careful patient selection, initiation of a low dose with gradual escalation and monitoring for side effects may result in an improved therapeutic response.
